Loading…

Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double‐hit high‐grade B‐cell lymphoma, and single‐hit MYC‐rearranged diffuse large B‐cell lymphoma

Background There are no immunophenotypic guidelines for the investigation of MYC‐rearranged lymphomas. We aimed to identify simple immunophenotypic features that would help to differentiate between MYC‐rearranged lymphomas and guide cytogenetic analysis. Methods We reviewed diagnostic samples from p...

Full description

Saved in:
Bibliographic Details
Published in:Cytometry. Part B, Clinical cytometry Clinical cytometry, 2020-09, Vol.98 (5), p.412-420
Main Authors: Tsagarakis, Nikolaos J., Papadhimitriou, Stefanos I., Pavlidis, Dimitris, Liapis, Konstantinos, Gortzolidis, Georgios, Kostopoulos, Ioannis V., Marinakis, Theodoros, Paterakis, Georgios
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4457-c25d80edff7a316d34f657af559545f62e94fe5a112ba7d16595d877648152ae3
cites cdi_FETCH-LOGICAL-c4457-c25d80edff7a316d34f657af559545f62e94fe5a112ba7d16595d877648152ae3
container_end_page 420
container_issue 5
container_start_page 412
container_title Cytometry. Part B, Clinical cytometry
container_volume 98
creator Tsagarakis, Nikolaos J.
Papadhimitriou, Stefanos I.
Pavlidis, Dimitris
Liapis, Konstantinos
Gortzolidis, Georgios
Kostopoulos, Ioannis V.
Marinakis, Theodoros
Paterakis, Georgios
description Background There are no immunophenotypic guidelines for the investigation of MYC‐rearranged lymphomas. We aimed to identify simple immunophenotypic features that would help to differentiate between MYC‐rearranged lymphomas and guide cytogenetic analysis. Methods We reviewed diagnostic samples from patients diagnosed with Burkitt lymphoma (BL), double‐hit lymphoma (DHL), MYC‐rearranged diffuse large B‐cell lymphoma (MYC‐DLBCL), and standard (non‐MYC‐rearranged) DLBCL over the last decade in our Institution. Using flow cytometry (with antibodies CD20, CD10, CD38, bcl‐2, Ki‐67, FMC‐7, CD43, CD27, CD79b, CD23, and CD22) we determined antigen% expression and median‐fluorescence intensity ratios (MFIR). The forward scatter (FS) and side scatter (SS) characteristics of tumor B‐cells were compared with normal T‐cells (B/T ratios) for patients with MYC‐rearranged lymphomas. Results We identified 51 patients of whom 14 had BL, 10 had DHL (6 MYC+/BCL2+; 4 MYC+/BCL6+), 8 MYC‐DLBCL, and 19 standard DLBCL. The significant differences (p  90, CD10% > 80, CD10MFIR > 10, bcl‐2%  70 was characteristic of BL. “Deviation” from these cut‐offs should raise suspicion for DHL and, therefore, BCL2 and/or BCL6 FISH is required. We also found that a diagnosis of DHL rather than of MYC‐DLBCL was significantly associated with CD10% > 60, Ki‐67% > 50, and SS (B/T)
doi_str_mv 10.1002/cyto.b.21887
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2410350578</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2410350578</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4457-c25d80edff7a316d34f657af559545f62e94fe5a112ba7d16595d877648152ae3</originalsourceid><addsrcrecordid>eNp9kUFu1TAQhiMEEqWw4wCW2LDoe8SOHSdLXgQFqVU3ZdGV5STjxCWxg-0UZccRejduwElwGlRVqOpq_rG--T2aP0ne4nSP05R8aJZg9_We4KLgz5IjzBjZ0ZLx5_eali-TV95fp2nGaM6Pkt-VNcHpeg7aGmQV0uM4Gzv1YGxYJkDBotAD0uYGfNCdvOOkaVGrlQIHJmg5xEZ2xnrtV4vD7L7rENCwjFNvR3mCWjvXA_z5ddvrgHrd9VF2TraADlE1MAwP4NXca9PdD5xfVVE5kM5J08H29ewBDdJ1j1i8Tl4oOXh4868eJ98-f7qsvuzOLk6_Vh_Pdg2ljO8awtoihVYpLjOctxlVOeNSMVYyylROoKQKmMSY1JK3OI_vbcF5TgvMiITsOHm_-U7O_pjjecSo_bqJNGBnLwjF8cwp40VE3_2HXtvZmbhdpChNS4IzGqmTjWqc9d6BEpPTo3SLwKlYExZrwqIWdwlHnG74Tz3A8iQrqqvLi8M29hf8vrVF</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2444092134</pqid></control><display><type>article</type><title>Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double‐hit high‐grade B‐cell lymphoma, and single‐hit MYC‐rearranged diffuse large B‐cell lymphoma</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Tsagarakis, Nikolaos J. ; Papadhimitriou, Stefanos I. ; Pavlidis, Dimitris ; Liapis, Konstantinos ; Gortzolidis, Georgios ; Kostopoulos, Ioannis V. ; Marinakis, Theodoros ; Paterakis, Georgios</creator><creatorcontrib>Tsagarakis, Nikolaos J. ; Papadhimitriou, Stefanos I. ; Pavlidis, Dimitris ; Liapis, Konstantinos ; Gortzolidis, Georgios ; Kostopoulos, Ioannis V. ; Marinakis, Theodoros ; Paterakis, Georgios</creatorcontrib><description>Background There are no immunophenotypic guidelines for the investigation of MYC‐rearranged lymphomas. We aimed to identify simple immunophenotypic features that would help to differentiate between MYC‐rearranged lymphomas and guide cytogenetic analysis. Methods We reviewed diagnostic samples from patients diagnosed with Burkitt lymphoma (BL), double‐hit lymphoma (DHL), MYC‐rearranged diffuse large B‐cell lymphoma (MYC‐DLBCL), and standard (non‐MYC‐rearranged) DLBCL over the last decade in our Institution. Using flow cytometry (with antibodies CD20, CD10, CD38, bcl‐2, Ki‐67, FMC‐7, CD43, CD27, CD79b, CD23, and CD22) we determined antigen% expression and median‐fluorescence intensity ratios (MFIR). The forward scatter (FS) and side scatter (SS) characteristics of tumor B‐cells were compared with normal T‐cells (B/T ratios) for patients with MYC‐rearranged lymphomas. Results We identified 51 patients of whom 14 had BL, 10 had DHL (6 MYC+/BCL2+; 4 MYC+/BCL6+), 8 MYC‐DLBCL, and 19 standard DLBCL. The significant differences (p &lt;.05) were: higher CD38% in BL than standard DLBCL; higher CD10% in BL and DHL versus MYC‐DLBCL and standard DLBCL; higher CD10MFIR in BL than MYC‐DLBCL and standard DLBCL; higher Ki‐67% in BL than DHL and MYC‐DLBCL; higher bcl‐2% in DHL than BL; higher FMC‐7% in BL than MYC‐DLBCL and standard DLBCL; and lower SS (B/T) ratio in DHL than MYC‐DLBCL. Conclusions The combination of CD38% &gt; 90, CD10% &gt; 80, CD10MFIR &gt; 10, bcl‐2% &lt; 30, and Ki‐67% &gt; 70 was characteristic of BL. “Deviation” from these cut‐offs should raise suspicion for DHL and, therefore, BCL2 and/or BCL6 FISH is required. We also found that a diagnosis of DHL rather than of MYC‐DLBCL was significantly associated with CD10% &gt; 60, Ki‐67% &gt; 50, and SS (B/T) &lt;1.5.</description><identifier>ISSN: 1552-4949</identifier><identifier>EISSN: 1552-4957</identifier><identifier>DOI: 10.1002/cyto.b.21887</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley &amp; Sons, Inc</publisher><subject>Antibodies ; Antigens ; Bcl-6 protein ; Burkitt lymphoma ; Burkitt's lymphoma ; CD20 antigen ; CD22 antigen ; CD23 antigen ; CD27 antigen ; CD38 antigen ; CD43 antigen ; Cytogenetics ; Diagnosis ; Diagnostic systems ; Differential diagnosis ; DLBCL ; double‐hit lymphoma ; Flow cytometry ; Fluorescence ; Fluorescence in situ hybridization ; immunophenotype ; Lymphoma ; Myc protein ; MYC rearrangement ; Scattering</subject><ispartof>Cytometry. Part B, Clinical cytometry, 2020-09, Vol.98 (5), p.412-420</ispartof><rights>2020 International Clinical Cytometry Society</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4457-c25d80edff7a316d34f657af559545f62e94fe5a112ba7d16595d877648152ae3</citedby><cites>FETCH-LOGICAL-c4457-c25d80edff7a316d34f657af559545f62e94fe5a112ba7d16595d877648152ae3</cites><orcidid>0000-0002-9759-0048</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Tsagarakis, Nikolaos J.</creatorcontrib><creatorcontrib>Papadhimitriou, Stefanos I.</creatorcontrib><creatorcontrib>Pavlidis, Dimitris</creatorcontrib><creatorcontrib>Liapis, Konstantinos</creatorcontrib><creatorcontrib>Gortzolidis, Georgios</creatorcontrib><creatorcontrib>Kostopoulos, Ioannis V.</creatorcontrib><creatorcontrib>Marinakis, Theodoros</creatorcontrib><creatorcontrib>Paterakis, Georgios</creatorcontrib><title>Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double‐hit high‐grade B‐cell lymphoma, and single‐hit MYC‐rearranged diffuse large B‐cell lymphoma</title><title>Cytometry. Part B, Clinical cytometry</title><description>Background There are no immunophenotypic guidelines for the investigation of MYC‐rearranged lymphomas. We aimed to identify simple immunophenotypic features that would help to differentiate between MYC‐rearranged lymphomas and guide cytogenetic analysis. Methods We reviewed diagnostic samples from patients diagnosed with Burkitt lymphoma (BL), double‐hit lymphoma (DHL), MYC‐rearranged diffuse large B‐cell lymphoma (MYC‐DLBCL), and standard (non‐MYC‐rearranged) DLBCL over the last decade in our Institution. Using flow cytometry (with antibodies CD20, CD10, CD38, bcl‐2, Ki‐67, FMC‐7, CD43, CD27, CD79b, CD23, and CD22) we determined antigen% expression and median‐fluorescence intensity ratios (MFIR). The forward scatter (FS) and side scatter (SS) characteristics of tumor B‐cells were compared with normal T‐cells (B/T ratios) for patients with MYC‐rearranged lymphomas. Results We identified 51 patients of whom 14 had BL, 10 had DHL (6 MYC+/BCL2+; 4 MYC+/BCL6+), 8 MYC‐DLBCL, and 19 standard DLBCL. The significant differences (p &lt;.05) were: higher CD38% in BL than standard DLBCL; higher CD10% in BL and DHL versus MYC‐DLBCL and standard DLBCL; higher CD10MFIR in BL than MYC‐DLBCL and standard DLBCL; higher Ki‐67% in BL than DHL and MYC‐DLBCL; higher bcl‐2% in DHL than BL; higher FMC‐7% in BL than MYC‐DLBCL and standard DLBCL; and lower SS (B/T) ratio in DHL than MYC‐DLBCL. Conclusions The combination of CD38% &gt; 90, CD10% &gt; 80, CD10MFIR &gt; 10, bcl‐2% &lt; 30, and Ki‐67% &gt; 70 was characteristic of BL. “Deviation” from these cut‐offs should raise suspicion for DHL and, therefore, BCL2 and/or BCL6 FISH is required. We also found that a diagnosis of DHL rather than of MYC‐DLBCL was significantly associated with CD10% &gt; 60, Ki‐67% &gt; 50, and SS (B/T) &lt;1.5.</description><subject>Antibodies</subject><subject>Antigens</subject><subject>Bcl-6 protein</subject><subject>Burkitt lymphoma</subject><subject>Burkitt's lymphoma</subject><subject>CD20 antigen</subject><subject>CD22 antigen</subject><subject>CD23 antigen</subject><subject>CD27 antigen</subject><subject>CD38 antigen</subject><subject>CD43 antigen</subject><subject>Cytogenetics</subject><subject>Diagnosis</subject><subject>Diagnostic systems</subject><subject>Differential diagnosis</subject><subject>DLBCL</subject><subject>double‐hit lymphoma</subject><subject>Flow cytometry</subject><subject>Fluorescence</subject><subject>Fluorescence in situ hybridization</subject><subject>immunophenotype</subject><subject>Lymphoma</subject><subject>Myc protein</subject><subject>MYC rearrangement</subject><subject>Scattering</subject><issn>1552-4949</issn><issn>1552-4957</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kUFu1TAQhiMEEqWw4wCW2LDoe8SOHSdLXgQFqVU3ZdGV5STjxCWxg-0UZccRejduwElwGlRVqOpq_rG--T2aP0ne4nSP05R8aJZg9_We4KLgz5IjzBjZ0ZLx5_eali-TV95fp2nGaM6Pkt-VNcHpeg7aGmQV0uM4Gzv1YGxYJkDBotAD0uYGfNCdvOOkaVGrlQIHJmg5xEZ2xnrtV4vD7L7rENCwjFNvR3mCWjvXA_z5ddvrgHrd9VF2TraADlE1MAwP4NXca9PdD5xfVVE5kM5J08H29ewBDdJ1j1i8Tl4oOXh4868eJ98-f7qsvuzOLk6_Vh_Pdg2ljO8awtoihVYpLjOctxlVOeNSMVYyylROoKQKmMSY1JK3OI_vbcF5TgvMiITsOHm_-U7O_pjjecSo_bqJNGBnLwjF8cwp40VE3_2HXtvZmbhdpChNS4IzGqmTjWqc9d6BEpPTo3SLwKlYExZrwqIWdwlHnG74Tz3A8iQrqqvLi8M29hf8vrVF</recordid><startdate>202009</startdate><enddate>202009</enddate><creator>Tsagarakis, Nikolaos J.</creator><creator>Papadhimitriou, Stefanos I.</creator><creator>Pavlidis, Dimitris</creator><creator>Liapis, Konstantinos</creator><creator>Gortzolidis, Georgios</creator><creator>Kostopoulos, Ioannis V.</creator><creator>Marinakis, Theodoros</creator><creator>Paterakis, Georgios</creator><general>John Wiley &amp; Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9759-0048</orcidid></search><sort><creationdate>202009</creationdate><title>Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double‐hit high‐grade B‐cell lymphoma, and single‐hit MYC‐rearranged diffuse large B‐cell lymphoma</title><author>Tsagarakis, Nikolaos J. ; Papadhimitriou, Stefanos I. ; Pavlidis, Dimitris ; Liapis, Konstantinos ; Gortzolidis, Georgios ; Kostopoulos, Ioannis V. ; Marinakis, Theodoros ; Paterakis, Georgios</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4457-c25d80edff7a316d34f657af559545f62e94fe5a112ba7d16595d877648152ae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antibodies</topic><topic>Antigens</topic><topic>Bcl-6 protein</topic><topic>Burkitt lymphoma</topic><topic>Burkitt's lymphoma</topic><topic>CD20 antigen</topic><topic>CD22 antigen</topic><topic>CD23 antigen</topic><topic>CD27 antigen</topic><topic>CD38 antigen</topic><topic>CD43 antigen</topic><topic>Cytogenetics</topic><topic>Diagnosis</topic><topic>Diagnostic systems</topic><topic>Differential diagnosis</topic><topic>DLBCL</topic><topic>double‐hit lymphoma</topic><topic>Flow cytometry</topic><topic>Fluorescence</topic><topic>Fluorescence in situ hybridization</topic><topic>immunophenotype</topic><topic>Lymphoma</topic><topic>Myc protein</topic><topic>MYC rearrangement</topic><topic>Scattering</topic><toplevel>online_resources</toplevel><creatorcontrib>Tsagarakis, Nikolaos J.</creatorcontrib><creatorcontrib>Papadhimitriou, Stefanos I.</creatorcontrib><creatorcontrib>Pavlidis, Dimitris</creatorcontrib><creatorcontrib>Liapis, Konstantinos</creatorcontrib><creatorcontrib>Gortzolidis, Georgios</creatorcontrib><creatorcontrib>Kostopoulos, Ioannis V.</creatorcontrib><creatorcontrib>Marinakis, Theodoros</creatorcontrib><creatorcontrib>Paterakis, Georgios</creatorcontrib><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cytometry. Part B, Clinical cytometry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tsagarakis, Nikolaos J.</au><au>Papadhimitriou, Stefanos I.</au><au>Pavlidis, Dimitris</au><au>Liapis, Konstantinos</au><au>Gortzolidis, Georgios</au><au>Kostopoulos, Ioannis V.</au><au>Marinakis, Theodoros</au><au>Paterakis, Georgios</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double‐hit high‐grade B‐cell lymphoma, and single‐hit MYC‐rearranged diffuse large B‐cell lymphoma</atitle><jtitle>Cytometry. Part B, Clinical cytometry</jtitle><date>2020-09</date><risdate>2020</risdate><volume>98</volume><issue>5</issue><spage>412</spage><epage>420</epage><pages>412-420</pages><issn>1552-4949</issn><eissn>1552-4957</eissn><abstract>Background There are no immunophenotypic guidelines for the investigation of MYC‐rearranged lymphomas. We aimed to identify simple immunophenotypic features that would help to differentiate between MYC‐rearranged lymphomas and guide cytogenetic analysis. Methods We reviewed diagnostic samples from patients diagnosed with Burkitt lymphoma (BL), double‐hit lymphoma (DHL), MYC‐rearranged diffuse large B‐cell lymphoma (MYC‐DLBCL), and standard (non‐MYC‐rearranged) DLBCL over the last decade in our Institution. Using flow cytometry (with antibodies CD20, CD10, CD38, bcl‐2, Ki‐67, FMC‐7, CD43, CD27, CD79b, CD23, and CD22) we determined antigen% expression and median‐fluorescence intensity ratios (MFIR). The forward scatter (FS) and side scatter (SS) characteristics of tumor B‐cells were compared with normal T‐cells (B/T ratios) for patients with MYC‐rearranged lymphomas. Results We identified 51 patients of whom 14 had BL, 10 had DHL (6 MYC+/BCL2+; 4 MYC+/BCL6+), 8 MYC‐DLBCL, and 19 standard DLBCL. The significant differences (p &lt;.05) were: higher CD38% in BL than standard DLBCL; higher CD10% in BL and DHL versus MYC‐DLBCL and standard DLBCL; higher CD10MFIR in BL than MYC‐DLBCL and standard DLBCL; higher Ki‐67% in BL than DHL and MYC‐DLBCL; higher bcl‐2% in DHL than BL; higher FMC‐7% in BL than MYC‐DLBCL and standard DLBCL; and lower SS (B/T) ratio in DHL than MYC‐DLBCL. Conclusions The combination of CD38% &gt; 90, CD10% &gt; 80, CD10MFIR &gt; 10, bcl‐2% &lt; 30, and Ki‐67% &gt; 70 was characteristic of BL. “Deviation” from these cut‐offs should raise suspicion for DHL and, therefore, BCL2 and/or BCL6 FISH is required. We also found that a diagnosis of DHL rather than of MYC‐DLBCL was significantly associated with CD10% &gt; 60, Ki‐67% &gt; 50, and SS (B/T) &lt;1.5.</abstract><cop>Hoboken, USA</cop><pub>John Wiley &amp; Sons, Inc</pub><doi>10.1002/cyto.b.21887</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-9759-0048</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1552-4949
ispartof Cytometry. Part B, Clinical cytometry, 2020-09, Vol.98 (5), p.412-420
issn 1552-4949
1552-4957
language eng
recordid cdi_proquest_miscellaneous_2410350578
source Wiley-Blackwell Read & Publish Collection
subjects Antibodies
Antigens
Bcl-6 protein
Burkitt lymphoma
Burkitt's lymphoma
CD20 antigen
CD22 antigen
CD23 antigen
CD27 antigen
CD38 antigen
CD43 antigen
Cytogenetics
Diagnosis
Diagnostic systems
Differential diagnosis
DLBCL
double‐hit lymphoma
Flow cytometry
Fluorescence
Fluorescence in situ hybridization
immunophenotype
Lymphoma
Myc protein
MYC rearrangement
Scattering
title Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double‐hit high‐grade B‐cell lymphoma, and single‐hit MYC‐rearranged diffuse large B‐cell lymphoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T19%3A43%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Contribution%20of%20immunophenotype%20to%20the%20investigation%20and%20differential%20diagnosis%20of%20Burkitt%20lymphoma,%20double%E2%80%90hit%20high%E2%80%90grade%20B%E2%80%90cell%20lymphoma,%20and%20single%E2%80%90hit%20MYC%E2%80%90rearranged%20diffuse%20large%20B%E2%80%90cell%20lymphoma&rft.jtitle=Cytometry.%20Part%20B,%20Clinical%20cytometry&rft.au=Tsagarakis,%20Nikolaos%20J.&rft.date=2020-09&rft.volume=98&rft.issue=5&rft.spage=412&rft.epage=420&rft.pages=412-420&rft.issn=1552-4949&rft.eissn=1552-4957&rft_id=info:doi/10.1002/cyto.b.21887&rft_dat=%3Cproquest_cross%3E2410350578%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4457-c25d80edff7a316d34f657af559545f62e94fe5a112ba7d16595d877648152ae3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2444092134&rft_id=info:pmid/&rfr_iscdi=true